Successful surgical management of primary abdominal wall mucormycosis in an immunocompetent patient
Keywords:Primary cutaneous mucormycosis, Immunocompetent, Abdominal wall, Skin grafting
Primary abdominal wall mucormycosis rarely occur in immunocompetent, non-diabetic patients but may affectin patients with traumatic injury with contaminated wounds and patients underlying malignancies usually infiltrating into skin. Herein we are reporting a case of primary cutaneous mucormycosis in a 17-year-old male without immunodeficiency or any comorbidity. He was managed with multiple debridement of the wound and intravenous amphotericin B therapy with cumulative dose of 2000 mg of liposomal amphotericin B followed by split skin grafting. We would like to emphasize the importance of high index of suspicionof fungal sepsis and early start of antifungal therapy in this condition can reduce high rate of mortality and management of large wound with split skin grafting in same setting to avoid morbidity.
Paltauf A. Mucormycosismucorina. Virchows Arch Pathol Anat.1885;102:543-64.
Tapish S, Taha M, Naresh G. Primary mucormycosis of abdominal wall: A rare fungal infection in a immunocompetent patient. Indian J Surg. 2010;72:306-8.
Alan MS. Agents of mucormycosis & related species. In Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Gerald LM, John EB, Raphael D, (Eds.). 6th edition. Churchill Livingstone, Philadelphia. 2005;2973-84.
Tehmeena W, Hussain W, Zargar HR, Sheikh AR, Iqbal S. Primary cutaneous mucormycosis in an immunocompetent host. Mycopathologia. 2007;164:197-9.
Kwon-Chung KJ, Bennett JW. Medical Mycology. Philadelphia Lea and Febiger. 1992.
Baraia J, Munoz P. Cutaneous mucormycosis in a heart transplant patient associated with a peripheral catheter. Eur J Clin Microbiol Infect Dis. 1995;14:813-5.
Ng TC, Denning DW. Liposomal Amphotericin B (AmBisome) therapy in invasive fungal infections. Arch Intern Med. 1995;155:1093-8.
Mileshkin L, Slavin M, Seymour JF, Mckenzie A. Successful treatment of rhinocerebralzygomycosis using liposomal nystatin. Leuk Lymph. 2001;42:1119-23.